Substituted chromanes and method of use

Abstract

The invention provides for compounds of formula (I) wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

We claim: 
     
         1 . A compound: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . A pharmaceutical composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         3 . A method for treating cystic fibrosis in a subject comprising administering a therapeutically effective amount of a compound of  claim 1  or a pharmaceutically acceptable salt thereof, to a subject in need thereof.